Danaher Co. (NYSE:DHR) Receives $268.27 Consensus Target Price from Analysts

Shares of Danaher Co. (NYSE:DHR) have received an average recommendation of “Moderate Buy” from the sixteen analysts that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $270.00.

Several equities research analysts have recently commented on the company. Bank of America lifted their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. TD Cowen boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James lifted their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, Royal Bank of Canada increased their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,132 shares of company stock worth $21,022,795. Company insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Bogart Wealth LLC increased its holdings in Danaher by 25.9% in the 1st quarter. Bogart Wealth LLC now owns 32,423 shares of the conglomerate’s stock valued at $8,097,000 after buying an additional 6,677 shares during the period. Lindbrook Capital LLC boosted its position in shares of Danaher by 12.2% during the 1st quarter. Lindbrook Capital LLC now owns 5,423 shares of the conglomerate’s stock worth $1,354,000 after acquiring an additional 591 shares in the last quarter. Osborne Partners Capital Management LLC raised its position in Danaher by 2.0% during the first quarter. Osborne Partners Capital Management LLC now owns 91,322 shares of the conglomerate’s stock valued at $22,805,000 after purchasing an additional 1,768 shares in the last quarter. Schnieders Capital Management LLC bought a new stake in Danaher during the first quarter worth $205,000. Finally, Capital Investment Advisory Services LLC boosted its holdings in shares of Danaher by 1.5% in the 1st quarter. Capital Investment Advisory Services LLC now owns 3,642 shares of the conglomerate’s stock valued at $909,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $245.82 on Tuesday. The business has a fifty day moving average of $248.94 and a 200-day moving average of $230.88. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00. The firm has a market cap of $182.04 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the firm posted $2.36 earnings per share. The company’s revenue was down 2.6% on a year-over-year basis. On average, equities research analysts predict that Danaher will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.